Castalian Partners’s Inhibrx INBX Stock Holding History

Castalian Partners’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-191,533	Closed	-$2.95M	–	19
2024 Q4	$2.95M	Buy	+191,533	New	+$2.92M	1.49%	20

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Slotnik Capital Dallas, Texas $342M AUM 105.92% 1-Year Est. Return

Castalian Partners's INBX Position: Q1 2025 in Review

Castalian Partners sold out of Inhibrx (INBX) in Q1 2025, closing a stake of 191,533 shares — an estimated $2.95M sold.

Castalian Partners first reported a position in INBX in Q4 2024 and held it in 1 quarter. The position peaked at $2.95M in Q4 2024. 92 funds tracked by Wall St. Rank hold INBX as of Q1 2025.

Castalian Partners reported no remaining Inhibrx position as of Q1 2025 after selling out during the quarter.
Castalian Partners sold 191,533 Inhibrx shares in Q1 2025, an estimated $2.95M.
Castalian Partners first reported a position in Inhibrx in Q4 2024 and held it in 1 quarter.
Castalian Partners's Inhibrx position peaked at $2.95M in Q4 2024.
92 funds tracked by Wall St. Rank held Inhibrx as of Q1 2025.

Based on Castalian Partners's 13F filing for Q1 2025, filed 15 May 2025.